Iomai (now part of Intercell) needed a device to reliably deliver their transcutaneous vaccine in the hands of non-specialist users.
Starting with an investigation into technology approaches, the team created a device platform from the ground up, creating patentable technology along the way.
To ensure that anyone could successfully deliver the vaccine, we worked directly with nurses, evolving the device mechanism and interface, including developing visual DFU's to maximize performance.
Johnson & Johnson
A subsidiary of Johnson & Johnson developed a novel approach to an in-office pediatric ENT procedure.
The team worked with their marketing and development teams to define a system approach to maximize the safety and efficacy of the treatment. This included qualitative research with parents, ENT surgeons, nurses and child development experts.
In addition to defining a complete system of 'props' to keep infants calm and still, we created training guides for nurses and take-home informative storybooks for parents to inform their children (and themselves) about the procedure they were about to undergo.
In bringing the next generation of monoclonal antibody (mAb) therapies to market, Eli Lilly wanted to deliver a best-in-class drug delivery experience, while staking out a technology platform in a crowded IP space.
The design team started by understanding the real needs and struggles of patients and caregivers in the target market: what features would both differentiate a new device and make it easier to use?
Guided by this insight, the team invented an unprecedentedly simple and intuitive interface. In a study, 94% of people said the Trulicity pen was easy to use.